gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Olfactory receptor 628

Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. The nomenclature assigned to the olfactory receptor genes and proteins for this organism is independent of other organisms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: mu-opioid receptor, Interferon-alpha, HAD, Tec, AGE
Papers on MOR-22
[Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors].
Koiso et al., In Hinyokika Kiyo, 1992
The combination therapy with natural type human tumor necrosis factor (n-TNF; MHR-24) and human lymphoblastoid interferon-alpha (n-IFN-alpha; MOR-22) was investigated for antitumor effect against renal cell carcinoma in a multiclinic cooperative study throughout Japan.
[Clinical effects and immunological changes in interferon therapy for advanced renal cell carcinoma].
Suzuki et al., Hirosaki, Japan. In Nihon Gan Chiryo Gakkai Shi, 1990
alpha-type Interferon (INF-alpha A, MOR-22, HLBI) or gamma-type Interferon (GI-3) was administered intramuscularly to 18 patients with advanced renal cell carcinoma to examine its antitumor effect and immunological changes.
[Combination therapy of renal cell carcinoma with interferon-alpha and UFT (or FT-207)].
Kitaura et al., In Nihon Gan Chiryo Gakkai Shi, 1989
Human lymphoblastoid interferon (IFN-alpha MOR-22; OIF) was administered to forty-two patients suffering from renal cell carcinoma.
Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials.
Niijima et al., In Cancer, 1986
A cooperative study was carried out in 44 institutions in Japan to evaluate the clinical efficacy of two kinds of recombinant human leukocyte interferon (Ro 22-8181 and Sch 30500) and a human lymphoblastoid interferon (MOR-22) on metastatic lesions of renal cell carcinoma.
[Effect of interferon-alpha (MOR-22) on human NK cell activity].
Hirai et al., In Gan To Kagaku Ryoho, 1986
We studied the effect of human lymphoblastoid interferon (IFN-alpha; MOR-22) on the natural killer (NK) cell activity of human peripheral blood lymphocytes (PBL).
[Study on human lymphoblastoid interferon-alpha (MOR-22): Part III. Antitumor effect on nude mouse-transplanted human tumors].
Kiyonaga et al., In Gan To Kagaku Ryoho, 1986
The effects of human lymphoblastoid interferon-alpha (MOR-22) on the growth of xenografted human tumors in nude mice were examined.
[Basic study on human lymphoblastoid interferon-alpha (MOR-22): Part I. Antiviral effect].
Horisawa et al., In Gan To Kagaku Ryoho, 1986
A study was performed on the antiviral effects of human interferon-alpha (MOR-22) produced by a human lymphoblastoid cell line (BALL-1).
[Study on human lymphoblastoid interferon-alpha (MOR-22): Part II. Anticellular effects].
Nobuhara et al., In Gan To Kagaku Ryoho, 1986
The direct and indirect anti-cell proliferation effects of IFN-alpha produced by BALL-1 cells were examined.
[Antiproliferative activities of interferon-alpha].
Shirahama et al., In Gan To Kagaku Ryoho, 1985
The antiproliferative activities of human lymphoblastoid interferon-alpha (MOR-22) against 22 cultured human cell lines were examined.
share on facebooktweetadd +1mail to friends